KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Operations: 2009-2024

Historic Cash from Operations for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $479.1 million.

  • Halozyme Therapeutics' Cash from Operations rose 54.80% to $178.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $611.0 million, marking a year-over-year increase of 51.63%. This contributed to the annual value of $479.1 million for FY2024, which is 23.29% up from last year.
  • As of FY2024, Halozyme Therapeutics' Cash from Operations stood at $479.1 million, which was up 23.29% from $388.6 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Cash from Operations ranged from a high of $479.1 million in FY2024 and a low of $55.5 million during FY2020.
  • For the 3-year period, Halozyme Therapeutics' Cash from Operations averaged around $369.2 million, with its median value being $388.6 million (2023).
  • In the last 5 years, Halozyme Therapeutics' Cash from Operations soared by 439.98% in 2021 and then decreased by 19.81% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Cash from Operations (Yearly) stood at $55.5 million in 2020, then spiked by 439.98% to $299.4 million in 2021, then decreased by 19.81% to $240.1 million in 2022, then skyrocketed by 61.83% to $388.6 million in 2023, then increased by 23.29% to $479.1 million in 2024.